四川汇宇制药股份有限公司 独立董事关于第二届董事会第三次会议相关事项 的独立意见 综上，我们对于《2023 年半年度募集资金存放与实际使用情况的专项报告》 无异议。 （以下无正文） （本页无正文，为《四川汇宇制药股份有限公司独立董事关于第二届董事会第 三次会议相关事项的独立意见》签字页） 独立董事： 龙永强 梁昕昕 郭云沛 我们作为四川汇宇制药股份有限公司（以下简称"公司"）的独立董事，根据 《中华人民共和国公司法》（以下简称"公司法"）《中华人民共和国证券法》 （以下简称"证券法"）《上市公司股权激励管理办法》（以下简称"管理办法"） 《上海证券交易所科创板股票上市规则》（以下简称"上市规则"）《上市公司 独立董事管理办法》等法律、法规及《公司章程》有关等规定，本着谨慎的原则， 基于独立判断的立场，现对公司第二届董事会第三次会议的相关事项进行了审核 并发表以下独立意见： 一、《关于公司<2023 年半年度募集资金存放与实际使用情况的专项报告> 的议案》的独立意见 经审阅，我们认为公司 2023 年半年度募集资金的存放和实际使用符合中国 证监会、上海证券交易所关于上市公司募集资金存放和使用的相关监管要求和管 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2023-103 四川汇宇制药股份有限公司 监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （4）在提出本意见前，未发现参与公司 2023 年半年度报告编制的人员和审 议人员有违反保密规定的行为。 综上，监事会一致同意《2023 年半年度报告》及其摘要。 一、 监事会会议召开情况 四川汇宇制药股份有限公司（以下简称"公司"）第二届监事会第三次会议 于 2023 年 8 月 18 日以电子邮件方式发出通知，并于 2023 年 8 月 28 日在公司会 议室以现场结合通讯表决方式召开。本次会议由公司监事会主席邓玲女士召集并 主持，应出席监事 3 人，实际出席监事 3 人。全体监事认可本次会议的通知时间、 议案内容等事项，本次监事会的召集和召开程序符合《中华人民共和国公司法》 《中华人民共和国证券法》等法律法规及《四川汇宇制药股份有限公司章程》的 相关规定，会议决议合法有效。 二、监事会会议审议情况 （一）审议通过《关于公司<2023 年半年度报告>及摘要的议 ...

董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 四川汇宇制药股份有限公司（以下简称"公司"）第二届董事会第三次会议 于 2023 年 8 月 28 日以现场结合通讯表决方式在四川省内江市市中区汉阳路 333 号 3 幢公司 4 楼会议室召开。会议通知和会议资料已于 2023 年 8 月 18 日以电子 邮件方式发出。本次会议由董事长丁兆先生主持，会议应出席董事 9 人，实际出 席董事 9 人，相关监事及高管列席。全体董事一致同意并认可本次会议的通知和 召开时间、议案内容等事项，本次董事会会议的召集和召开程序符合有关法律、 行政法规、部门规章、规范性文件和《公司章程》的规定，作出的决议合法、有 效。 证券代码：汇宇制药 证券简称：688553 公告编号：2023-102 四川汇宇制药股份有限公司 公司 2023 年半年度募集资金存放与实际使用情况符合《上海证券交易所科 创板上市公司自律监管指引第 1 号—规范运作》等有关法律、法规和规范性文件 的规定。 表决结果：9 票赞成；0 票弃权 ...

| 药品名称 | 普乐沙福注射液 | | --- | --- | | 剂型 | 注射剂 | | 规格 | 1.2ml:24mg | | 适应症 | 普乐沙福注射液与粒细胞集落刺激因子（G-CSF）联用，适用 于非霍奇金淋巴瘤（NHL）和多发性骨髓瘤（MM）患者动员 造血干细胞（HSC）进入外周血，以便于完成HSC采集与自体 | | | 移植。 | | 申请人 | Seacross Pharma (Europe) Ltd. | | 受理号 | n/a | | 上市许可号： | 050541010 | 一、药品基本情况 二、药品的其他相关情况 普乐沙福注射液与粒细胞集落刺激因子（G-CSF）联用，适用于非霍奇金淋 巴瘤（NHL）和多发性骨髓瘤（MM）患者动员造血干细胞（HSC）进入外周血， 以便于完成 HSC 采集与自体移植。 公司普乐沙福注射液研发成功后已进行了多国注册申报，分别已在中国、英 证券代码：688553 证券简称：汇宇制药 公告编号：2023-101 四川汇宇制药股份有限公司 关于自愿披露普乐沙福注射液获得意大利上市许可的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者 ...

2023 年第一季度报告 证券代码：688553 证券简称：汇宇制药 四川汇宇制药股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 | | 单位：元 | | 币种：人民币 | | --- | --- | --- | --- | | 项目 | 本报告期 | 本报告期比上年同 | | | | | 期增减变动幅度 | | | | | (%) | | | 营业收入 | 237,720,069.60 | | -49.04 | | 归属于上市公司股东的净利润 | 38,395,308.10 | | -67.79 | | 归属于上市公司股东的扣除非经常 | 17,819,514.67 | | ...

Financial Performance - The net profit attributable to the parent company for 2022 was RMB 248,990,617.28, with a cumulative distributable profit of RMB 816,516,589.68 as of December 31, 2022[7]. - The proposed cash dividend is RMB 2.35 per 10 shares (including tax), totaling RMB 99,546,000.00, which accounts for 40.00% of the net profit attributable to the parent company for 2022[7]. - The company's operating revenue for 2022 was CNY 1,493,267,942.75, a decrease of 18.12% compared to CNY 1,823,733,127.05 in 2021[42]. - The net profit attributable to shareholders decreased by 44.15% to CNY 248,990,617.28 in 2022, down from CNY 445,858,609.04 in 2021[42]. - Basic earnings per share fell by 50.83% to CNY 0.59 in 2022, compared to CNY 1.20 in 2021[43]. - The weighted average return on equity decreased to 6.85% in 2022 from 32.59% in 2021, a decline of 25.74%[44]. - The company's operating profit decreased by 50.82% to CNY 235.45 million, reflecting the challenges faced in the current market environment[137]. - The net profit for the reporting period was 248.99 million yuan, a decrease of 44.15% compared to the same period last year, primarily due to a decline in operating income and an increase in R&D expenses[142]. Risks and Challenges - The company faces risks of declining sales prices and reduced sales revenue due to national centralized procurement from 2023 to 2025, impacting main business income significantly[4]. - The company is exposed to risks from potential price declines of drugs due to government policies such as price negotiations and procurement adjustments[131]. - Changes in the national medical insurance catalog could impact the sales growth of the company's products if they are removed from the list[132]. - The company faces risks related to the loss of core technical personnel, which is critical for maintaining its competitive edge in R&D and production[114]. - The company is subject to environmental regulations that may increase operational costs if stricter standards are implemented[117]. - The pharmaceutical industry is experiencing intensified competition, with domestic companies rapidly advancing, posing risks to market share and profitability[133]. Research and Development - Research and development expenses increased by 43.50% to CNY 356,193,682.36 in 2022, up from CNY 248,212,224.68 in 2021[42]. - The proportion of R&D investment to operating revenue increased to 23.85% in 2022, up from 13.61% in 2021[44]. - The company has a total of 750 R&D personnel, with the proportion of master's and doctoral degree holders increasing from 29.60% to 32.70%[95]. - The company is focusing on innovative drug development, particularly in oncology, with a commitment to improving clinical value[109]. - The company has established advanced drug technology platforms, including a consistency evaluation platform for generic injectable drugs and a new drug technology platform for biological drugs[185]. - The company is actively pursuing the development of new products, with several injections for cancer treatment and other conditions currently under review[192]. Corporate Governance - The actual controller, Ding Zhao, holds special voting rights that grant him five votes per share compared to ordinary shares, giving him significant control over company decisions[10]. - The company has established a special voting rights mechanism to ensure the actual controller's influence over major decisions, which may limit the impact of other shareholders, particularly minority shareholders[17]. - The company has three independent directors who supervise corporate governance, enhancing the oversight of major related transactions and external guarantees[20]. - The company emphasizes cash dividends as a priority in profit distribution, ensuring sufficient cash flow for normal operations[22]. - The company is committed to protecting investors' legal rights through transparent information disclosure practices[23]. Market Presence and Product Development - The company has expanded its international market presence, with 18 products approved for sale abroad and nearly 270 registrations, including new sales in 9 countries in 2022[60]. - The company is developing high-tech II and III class medical devices, with 2 II class medical device registration applications submitted[56]. - The company has launched 11 high-quality generic drugs in the oncology field in China, with multiple products being the first or among the top three to pass consistency evaluations[59]. - The company is advancing 10 projects in the oncology treatment pipeline and aims to submit 2 IND applications for small molecule innovative drugs this year[56]. - The company has established a robust marketing network covering over 2,000 hospitals across all provinces in China, primarily utilizing bulk purchasing and academic promotion sales models[63]. Financial Management - The company has implemented a strict GMP management system to ensure standardized production processes and product quality[65]. - The company maintains a stable relationship with suppliers for key raw materials, but any disruption could adversely affect production[119]. - The company's inventory at the end of 2022 was valued at 165.98 million yuan, representing 5.78% of current assets, which poses a risk of inventory write-downs if market demand declines[127]. - The company reported a financial income of -46,898,621.39, a decrease of 4,194.31 compared to the previous year, attributed to increased interest income from cash management[162]. Future Outlook - The company has made a forward-looking statement regarding its future plans and strategies, cautioning investors about potential risks[24]. - The company plans to submit registration for several medical devices, including HY-2001 and HY-2002, with anticipated approval dates in 2025 and 2027 respectively[104]. - The company is focusing on expanding its product pipeline with multiple innovative drugs targeting various cancers and other diseases[188]. - The company is actively pursuing international collaborations and partnerships to enhance its market reach and product offerings[196].

证券代码：688553 证券简称：汇宇制药 公告编号： 2023-045 四川汇宇制药股份有限公司 关于参加 2022 年度制药专场集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 4 月 21 日(星期五)16:00 前通过邮件、电话、传真等形式将需要 了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普遍关注的 问题进行回答。 四川汇宇制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 6 日发 布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经 营成果、财务状况，公司参与了由上海证券交易所主办的 2022 年度制药专场集 体业绩说明会，此次活动将采用视频和网络文字互动的方式举行，投资者可登录 上海证券交易所上证路演中心（http://roadshow.sseinfo.com/）参与线上互动 交流。 一、 说明会类型 本次投资者说明会以视频和网络互动形式召开，公司将针对 2022 年度经营 成果及财务指标的具体情况与 ...

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 248,990,617.28 for the year 2022, with a cumulative distributable profit of RMB 816,516,589.68 as of December 31, 2022[6]. - The proposed cash dividend is RMB 2.35 per 10 shares (including tax), totaling RMB 99,546,000.00, which represents 40.00% of the net profit attributable to shareholders for 2022[6]. - The company's operating revenue for 2022 was approximately ¥1.49 billion, a decrease of 18.12% compared to ¥1.82 billion in 2021[37]. - The net profit attributable to shareholders decreased by 44.15% to ¥248.99 million in 2022 from ¥445.86 million in 2021[37]. - The basic earnings per share dropped by 50.83% to ¥0.59 in 2022 compared to ¥1.20 in 2021[38]. - The weighted average return on net assets fell to 6.85% in 2022 from 32.59% in 2021, a decrease of 25.74%[39]. - The net cash flow from operating activities decreased by 56.52% to ¥194.06 million in 2022 from ¥446.36 million in 2021[37]. - The company reported a total revenue of approximately ¥5.08 billion for the year 2022, with a net profit of around ¥331.34 million[100]. - The company achieved total operating revenue of 149,326.79 million RMB, a year-on-year decrease of 18.12% due to a significant decline in sales of its main product, pemetrexed disodium injection[130]. - The net profit attributable to shareholders was 24,899.06 million RMB, down 44.15% year-on-year, primarily due to the decline in sales revenue of key products[130]. Shareholder Rights and Governance - The company has established a special voting rights mechanism, where the actual controller holds special shares with five times the voting power of ordinary shares[9]. - As of the report date, the actual controller holds 31.28% of the total shares and 60.95% of the voting rights[12]. - The company has implemented measures to protect minority shareholders' interests, including the right to convene extraordinary general meetings and propose agenda items[15]. - The supervisory board will monitor the operation of the special voting rights mechanism to prevent abuse and ensure compliance with regulations[16]. - The independent directors are tasked with overseeing the company's governance and ensuring compliance with relevant laws and regulations[17]. - The company will strictly adhere to the disclosure requirements of the Shanghai Stock Exchange regarding special voting rights arrangements in its periodic reports[20]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a substantive commitment to investors, highlighting the importance of investment risk awareness[21]. - The company is committed to enhancing information disclosure management to protect investors' legal rights[20]. Research and Development - Research and development expenses increased by 43.50% to ¥356.19 million in 2022 from ¥248.21 million in 2021[37]. - The proportion of R&D investment to operating revenue increased to 23.85% in 2022 from 13.61% in 2021, an increase of 10.24%[39]. - The company has established four research institutes to enhance its capabilities in developing high-quality generic and innovative drugs, ensuring a robust pipeline[59]. - The company is focusing on enhancing its product portfolio with high-quality generic drugs to ensure sustainable growth in the future[50]. - The company is actively developing innovative drugs in oncology, with 12 projects in progress, including 7 small molecule drugs and 5 large molecule drugs, and has initiated 2 new projects during the reporting period[57]. - The company has completed FDA certification for its production quality management system, meeting international standards for entry into the U.S. market[53]. - The company has made significant progress in complex formulation production and quality control technologies, including advanced techniques for polymer excipient preparation and purification[82]. - The company has established advanced drug technology platforms, including consistency evaluation for generic drugs and quality control for raw materials[180]. - The company is focusing on innovative drug development, particularly in the oncology field, with a commitment to addressing clinical needs and reducing adverse reactions[104]. Market and Sales - The company has expanded its international market presence, with 18 products approved for sale abroad and nearly 270 registrations held, covering over 56 countries, including new sales in 9 countries in 2022[55]. - The domestic sales model primarily targets grade hospitals, utilizing bulk purchasing and academic promotion, while international sales are mainly conducted through a consignment model via subsidiaries[58]. - The company has a strong international registration system, enabling rapid global submissions and approvals, enhancing its competitive edge in international markets[87]. - The company has established partnerships for drug approvals in regions like Canada and the UAE[192]. - The company is strategically positioning itself in the oncology market with multiple anti-tumor products currently under review[188]. Risk Factors - The company has detailed risk factors and corresponding countermeasures in its management discussion and analysis section[4]. - The company faces risks related to intensified competition in the market, particularly concerning its main products entering volume-based procurement[110]. - The company is subject to environmental regulations that may increase operational costs if stricter standards are implemented in the future[112]. - The company is at risk of losing core technical personnel, which is critical for maintaining its competitive edge in R&D and production[109]. - The company faces risks from industry policy changes, price declines of drugs, and increased market competition, which could adversely affect business and profitability[125][126][128]. Product Development and Pipeline - The company is focusing on expanding its pipeline with innovative drugs, aiming for first-in-class and best-in-class status in the market[92]. - The company has several ongoing projects, including a biological innovative drug (HY-0001) with a total investment of CNY 430,000,000, currently in laboratory research, expected to enter preclinical studies in 2023[91]. - The company plans to launch multiple new drugs domestically and seek overseas authorization, targeting various cancers including non-small cell lung cancer and pancreatic cancer[91]. - The company is developing new technologies and formulations, including a combination product with G-CSF for mobilizing stem cells in patients[190]. - The company is actively pursuing regulatory approvals for its innovative therapies targeting serious health conditions, including various cancers and toxicities[96]. Financial Management - The company received government subsidies amounting to 12.90 million yuan during the reporting period, which are crucial for its operational performance[121]. - The company's financial expenses were -46,898,621.39 RMB, a significant reduction compared to the previous year, due to increased interest income from cash management[134]. - The company reported a net cash outflow from financing activities of 99.99 million yuan, a decrease of 244.72 million yuan year-on-year, mainly due to dividend payments[135]. - The company’s other income decreased by 48.97% to 12.90 million yuan, primarily due to a reduction in government subsidies[135]. - The company’s credit impairment losses increased by 48.5% to 7.70 million yuan, mainly due to an increase in bad debt provisions for other receivables[135].

2022 年第三季度报告 证券代码：688553 证券简称：汇宇制药 四川汇宇制药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 | 年初至报告期末 | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 上年同期增 | | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 386,863,922.44 | -23.65 | 1,220,116,9 ...

Shareholding Structure and Control - The company reported a total of 423,600,000 shares outstanding, with a shareholding structure where the controlling shareholder Ding Zhao holds 114,066,766 shares, including 80,466,766 special voting shares and 33,600,000 ordinary shares[9]. - Ding Zhao's special voting shares represent 19.00% of the total shares but account for 53.97% of the voting rights, significantly influencing corporate decisions[10]. - The company has implemented a special voting rights mechanism, allowing Ding Zhao to have five votes per special share compared to one vote per ordinary share, which may limit the influence of minority shareholders[12]. - The company has established a supervisory mechanism to monitor the operation of the special voting rights to protect the interests of minority shareholders[16]. - The company has three independent directors to enhance governance and ensure compliance with regulations during significant transactions[17]. - The company has committed to strict information disclosure practices regarding the implementation of special voting rights arrangements to protect investor interests[19]. - The company has not reported any non-operational fund occupation by the controlling shareholder or related parties[21]. Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2022, representing a year-over-year increase of 15%[27]. - The company reported a total revenue of ¥833.25 million for the first half of the year, a decrease of 5.88% compared to ¥885.29 million in the same period last year[33]. - Net profit attributable to shareholders was ¥169.70 million, down 34.13% from ¥257.62 million year-on-year[33]. - The company reported a total revenue of 4,791,851,820.00 RMB, with a net profit of 512,682,986.71 RMB for the first half of 2022[77]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in Q2 2022, representing a 25% year-over-year growth[132]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2022, representing a 20% year-over-year growth[150]. Research and Development - Research and development expenses increased by 25% to RMB 100 million, focusing on innovative drug development and clinical trials[27]. - R&D expenses increased by 55.53% to ¥170.71 million, representing 20.49% of total revenue, up from 12.40% in the previous year[34][35]. - The company aims to achieve a 10% annual growth rate in R&D investment during the 14th Five-Year Plan period, significantly higher than the previous 2%[49]. - The company has established five major technology platforms and two systems, focusing on high-quality generic drugs and innovative drug development[58]. - The company has made significant advancements in complex formulation production and quality control technologies, enhancing its competitive edge[53]. - The company is actively expanding its pipeline with increased investment in raw materials, excipients, and medical device R&D projects[63]. - The company has developed a comprehensive antibody and mRNA vaccine discovery technology platform, covering all stages from antibody screening to efficacy evaluation[56]. - The company has seen a notable increase in the number of high-level R&D personnel, contributing to the growth of its innovative drug pipeline[63]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2023[27]. - The company is expanding its market presence in Southeast Asia, targeting a 30% market share by the end of 2023[132]. - The company is considering strategic acquisitions to bolster its product offerings, with a budget of $H million earmarked for potential deals[135]. - The company is actively pursuing the renewal of procurement contracts for key products, which is expected to solidify sales performance during the renewal period[86]. Sustainability and Compliance - The company has initiated a sustainability program aimed at reducing operational costs by 10% over the next two years[27]. - The company has implemented measures to reduce carbon emissions, including encouraging employees to use environmentally friendly transportation and adopting more energy-efficient equipment[127]. - The company has established a clear decision-making process for related party transactions, ensuring compliance with legal and corporate governance standards[129]. - The company has committed to paying social insurance and housing funds for employees according to labor laws and regulations[144]. Shareholder Commitments and Governance - The company reported a commitment to avoid any competition with its main business, ensuring no direct or indirect engagement in similar businesses by its controlling shareholders[128]. - The commitment is irrevocable and effective from the date of signing until the earlier of the shareholder no longer holding more than 5% of the company's shares or the company ceasing to be listed on the Shanghai Stock Exchange[129]. - The company has pledged to compensate for any economic losses incurred due to violations of the commitment[128]. - The company has established measures to stabilize its stock price if it falls below 120% of the latest reported net asset value for 20 consecutive trading days[146]. Legal and Regulatory Compliance - The company confirmed that all documents provided for the initial public offering are true, accurate, and complete, with no false records or misleading statements[154]. - The company has not engaged in any fraudulent activities or misleading statements in its initial public offering documentation[149]. - The company has disclosed all related party transactions in accordance with securities regulations, ensuring transparency and compliance[129]. Operational Efficiency - The company is implementing new strategies to improve operational efficiency, targeting a 5% reduction in costs by the end of the fiscal year[132]. - The company reported a decrease in operating expenses by J%, improving overall profitability margins[137].